China has approved three COVID-19 vaccine candidates for clinical trials, with the recombinant adenovirus vector-based vaccine (Ad5-nCoV) listed as the world's first vaccine to go into phase two by the World Health Organization.
However, the researchers cautioned that the results should be interpreted carefully.
Given that it takes several years to develop an effective vaccine for a viral disease, world leading pharmaceutical companies and universities are in the race to develop a COVID-19 vaccine because the pandemic has infected almost five million people and killed almost 600,000 within five months.
There are reasons to be optimistic over the cutting-edge mRNA vaccines being developed to end the COVID-19 pandemic, according to an expert in the field.
These then recognise the spike protein and fight off the coronavirus, the researchers explained. If actual SARS-CoV-2 cells infect the body, the antibodies would understand the head protein and bind to it.
Perhaps the biggest issue that Ad5-nCoV may face in broader phase 2 trials is the inconsistency seen in its ability to generate an effective antibody and T-cell immune response.
To initiate the country's "self-reliance and self-sufficiency" for vaccine development, the IATF also backed the proposal of the DOST to create the Virology S&T Institute in New Clark City and the reactivation of the Pharmaceutical Development Unit at DOST-Industrial Technology Development Institute.
"Two factories will produce the vaccine". Efficacy is tracked by examining how well the vaccine stimulates the body's immune response, as measured by watching levels of T-cells and neutralizing antibodies. Antibodies needed for immunity peaked at 28 days after the inoculation.
Some of the participants, the researchers said, also exhibited a form of neutralising antibodies against SARS-CoV-2.
Meanwhile, the Ad5-nCoV vaccine also simulated a rapid T cell response in the majority of volunteers.
Approximately 39 per cent of those vaccinated experienced headaches while 17 per cent reported muscle pain. However, these adverse reactions persisted for less than 48 hours.
He urged the Wealth Health Organization to issue clear guidelines on a vaccine's use and distribution to prevent a vaccine first being made available to the rich at the expense of the people most in need.
The DOST will also be in charge of identifying the sites, the local institutions and the Filipino researchers who will be involved in the collaborative trials, he said. AstraZeneca has already signed an agreement to supply 100 million doses of the vaccine to the British government and it reiterated it hopes to start delivery in September.
Oxford University has tested a high-profile potential vaccine for COVID-19 which was unsuccessful in protecting monkeys from the novel coronavirus.